natgillin/translations-raw huggingface dataset:
The most common side effects with Viread (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, diarrhoea, dizziness, hypophosphataemia (low levels of phosphate in the blood), rash and asthenia (weakness).
Najpogostejši neželeni učinki zdravila Viread (opaženi pri več kot 1 bolniku od 10) so navzeja (slabost), bruhanje, driska, omotica, hipofosfatemija (nizke ravni fosfata v krvi), izpuščaji in astenija (oslabelost).
The most common side effects with Volibris (seen in more than 1 patient in 10) are headache (including sinus headache and migraine), peripheral oedema (swelling, especially of the ankles and feet) and fluid retention.
Najpogostejši neželeni učinki zdravila Volibris (opaženi pri več kot 1 bolniku od 10) so glavobol (vključno s sinusnim glavobolom in migreno), periferni edem (otekanje, zlasti gležnjev in stopal) ter zastajanje tekočin.
The most common side effects with Votubia (seen in more than 1 in 10 patients) are acne, stomatitis (inflammation of the lining of the mouth), upper respiratory tract infections (colds), nasopharyngitis (inflammation of the nose and throat), sinusitis (inflammation of the sinuses), otitis media (infection of the middle ear), pneumonia (infection of the lung), increased blood levels of cholesterol, irregular menstruation (periods) and amenorrhoea (absence of periods).
Najpogostejši neželeni učinki pri uporabi zdravila Votubia (opaženi pri več kot 1 bolniku od 10) so akne, stomatitis (vnetje ustne sluznice), okužbe zgornjih dihal (prehladi), nazofaringitis (okužbe nosu in žrela), sinuzitis (vnetje sinusov), vnetje srednjega ušesa, pljučnica (okužba pljuč), povečane ravni holesterola v krvi, neredne menstruacije in amenoreja (izostanek menstruacij).
The most common side effects with Xadago (which may affect up to 1 in 10 people) are insomnia (difficulty sleeping), dyskinesia (difficulty controlling movement), somnolence (sleepiness), dizziness, headache, worsening of existing Parkinson’s disease, cataract (clouding of the lens), orthostatic hypotension (drop in blood pressure when standing up), nausea (feeling sick) and falls.
Najpogostejši neželeni učinki zdravila Xadago (ki lahko prizadenejo največ 1 osebo od 10) so nespečnost, diskinezija (težave pri nadzoru gibov), somnolenca (zaspanost), omotica, glavobol, poslabšanje obstoječe Parkinsonove bolezni, katarakta (zameglitev očesne leče), ortostatska hipotenzija (upad krvnega tlaka ob vstajanju v pokončen položaj), navzeja (slabost) in padci.
The most common side effects with Xalkori (seen in more than 1 in 4 patients) are vision problems, nausea (feeling sick), diarrhoea, vomiting, oedema (swelling), increases in liver enzymes in the blood, decreased appetite, constipation, dizziness, neuropathy (pain due to nerve damage) and fatigue.
Najpogostejši neželeni učinki zdravila Xalkori (opaženi pri več kot 1 bolniku od 4) so motnje vida, navzeja (slabost), driska, bruhanje, edem (oteklina), povišanje jetrnih encimov v krvi, zmanjšanje teka, zaprtje, omotica, nevropatija (bolečine zaradi okvare živcev) in utrujenost.
The most common side effects with Xarelto (seen in between 1 and 10 patients in 100) are anaemia, dizziness, headache, bleeding in various parts of the body, hypotension (low blood pressure), haematoma (collection of blood under the skin), pain in the stomach and belly, dyspepsia (heartburn), nausea, constipation, diarrhoea, vomiting, pruritus (itching), rash, ecchymosis (bruising), pain in the extremities, decreased kidney function, fever, peripheral oedema (swelling, especially of the ankles and feet), decreased general strength and energy, increased levels of some liver enzymes in the blood and oozing of blood or fluid from the surgical wound in patients undergoing surgery.
Najpogostejši neželeni učinki zdravila Xarelto (opaženi pri 1 do 10 bolnikov od 100) so anemija, omotica, glavobol, krvavitve v različnih predelih telesa, hipotenzija (nizek krvni tlak), hematom (kopičenje krvi pod kožo), bolečine v želodcu in trebuhu, dispepsija (zgaga), navzeja (slabost), zaprtje, driska, bruhanje, pruritus (srbenje), izpuščaj, ekhimoze (modrice), bolečine v udih, zmanjšana ledvična funkcija, povišana telesna temperatura, periferni edem (otekanje, zlasti gležnjev in stopal), zmanjšanje splošne moči in energije, povečana raven nekaterih jetrnih encimov v krvi in izcedek krvi ali tekočine iz kirurške rane pri bolnikih po kirurškem posegu.
The most common side effects with Xeloda (seen in more than 1 patient in 10) are anorexia (loss of appetite), diarrhoea, vomiting, nausea (feeling sick), stomatitis (sores in the mouth), abdominal (tummy) pain, palmar-plantar erythrodysaesthesia syndrome (‘hand-foot syndrome’, a skin reaction with rash and pain on the hands and feet), fatigue (tiredness) and asthenia (weakness).
Najpogostejši neželeni učinki zdravila Xeloda (opaženi pri več kot 1 bolniku od 10) so anoreksija (izguba teka) driska, bruhanje, navzeja (slabost), stomatitis (razjede v ustih), bolečine v trebuhu, palmarno-plantarna eritrodisestezija („sindrom roka-noga“, kožna reakcija z izpuščaji in bolečinami v rokah in nogah), utrujenost in astenija (šibkost).
The most common side effects with Xgeva (seen in more than 1 patient in 10) are dyspnoea (difficulty breathing), diarrhoea and pain in the muscles and bones.
Najpogostejši neželeni učinki zdravila Xgeva (opaženi pri več kot 1 bolniku od 10) so dispneja (težave z dihanjem), driska ter bolečine v mišicah in kosteh.
The most common side effects with Xigduo (which may affect more than 1 in 10 people) are hypoglycaemia (when used together with insulin or a sulphonylurea) and gastrointestinal symptoms (symptoms affecting the stomach and gut).
Najpogostejši neželeni učinki zdravila Xigduo (ki lahko prizadenejo več kot 1 osebo od 10) so hipoglikemija (kadar se uporablja skupaj z insulinom ali sulfonilsečnino) in gastrointestinalni simptomi (simptomi, ki prizadenejo želodec in črevesje).
The most common side effects with Xofigo (which may affect more than 1 in 10 people) are diarrhoea, nausea (feeling sick), vomiting and thrombocytopenia (low blood-platelet counts).
Najpogostejši neželeni učinki zdravila Xofigo (ki lahko prizadenejo več 1 osebo od 10) so driska, navzea (slabost), bruhanje in trombocitopenija (majhno število trombocitov v krvi).
The most common side effects with Xtandi (which may affect more than 1 in 10 people) are tiredness, headache, hot flushes and hypertension (high blood pressure).
Najpogostejša neželena učinka zdravila Xtandi (ki lahko prizadeneta več kot 1 osebo od 10) so utrujenost, glavobol, vročinski valovi in hipertenzija (visok krvni tlak).
The most common side effects with ZACTRAN in cattle (which may affect more than 1 in 10 cattle) are swellings at the site of injection.
Najpogostejši neželeni učinek zdravila ZACTRAN pri govedu (ki lahko prizadene več kot 1 govedo od 10) je otekanje na mestu injiciranja.
The most common side effects with ZACTRAN in pigs (which may affect up to 1 in 10 pigs) are mild to moderate swellings at the site of injection.
Najpogostejši neželeni učinek zdravila ZACTRAN pri prašičih (ki lahko prizadene največ 1 prašiča od 10) je blago do zmerno otekanje na mestu injiciranja.
The most common side effects with Zaltrap (seen in more than 20 patients in 100) are leucopenia and neutropenia (low levels of white cells in the blood, including the type that fight infections), diarrhoea, proteinuria (protein in the urine), increased blood levels of liver enzymes (aspartate and alanine transaminases), stomatitis (inflammation of the mouth), fatigue, thrombocytopenia (low blood platelet counts), hypertension (high blood pressure), weight loss, decreased appetite, epistaxis (nose bleeds), abdominal pain, dysphonia (speech disturbance), increases in creatinine in the blood (a marker of kidney problems), and headache.
Najpogostejši neželeni učinki zdravila Zaltrap (opaženi pri več kot 20 bolnikih od 100) so levkopenija in nevtropenija (nizke ravni belih krvničk v krvi, vključno z vrsto, ki se bori proti okužbam), driska, proteinurija (beljakovine v urinu), povišane ravni jetrnih encimov v krvi (aspartat in alanin transaminaz), stomatitis (vnetje v ustih), utrujenost, trombocitopenija (nizko število trombocitov), hipertenzija (visok krvni tlak), zmanjšanje telesne mase, zmanjšanje teka, epistaksa (krvavitve iz nosu), bolečine v trebuhu, disfonija (motnje govora), zvišanje kreatinina v krvi (pokazalej težav z ledvicami) in glavobol.
The most common side effects with Zebinix (seen in more than 1 patient in 10) are dizziness and somnolence (sleepiness).
Najpogostejša neželena učinka zdravila Zebinix (opažena pri več kot 1 bolniku od 10) sta omotica in zaspanost.
The most common side effects with Zelboraf (seen in more than 30% of patients) include arthralgia (joint pain), fatigue (tiredness), rash, photosensitivity reaction (sunburn-like reactions following exposure to light), nausea (feeling sick), alopecia (hair loss) and pruritus (itching).
Najpogostejši neželeni učinki zdravila Zelboraf (opaženi pri več kot 30 %bolnikov) so artralgija (bolečine v sklepih), utrujenost, izpuščaji, fotosenzibilna reakcija (reakcije, podobne sončnim opeklinam, ki so posledica izpostavljenosti svetlobi), navzeja (slabost), alopecija (izpadanje las) in pruritus (srbenje).
The most common side effects with Zerbaxa (which may affect up to 1 in 10 people) are nausea (feeling sick), headache, constipation, diarrhoea and fever, which are generally mild or moderate.
Najpogostejši neželeni učinki zdravila Zerbaxa (ki lahko prizadenejo največ 1 osebo od 10) so navzea (slabost), glavobol, zaprtost, driska in povišana telesna temperatura, ki so običajno blagi ali zmerni.
The most common side effects with Zerene (seen in between 1 and 10 patients in 100) are amnesia (memory problems), paraesthesia (unusual sensations like pins and needles), somnolence (sleepiness) and dysmenorrhoea (painful menstruation).
Najpogostejši neželeni učinki zdravila Zerene (opaženi pri 1 do 10 bolnikih izmed 100) so amnezija (motnja spomina), parestezija (nenormalni občutki zbadanja), somnolenca (zaspanost) in dismenoreja (boleča menstruacija).
The most common side effects with Zinforo (seen in more than 3% of patients) are diarrhoea, headache, nausea (feeling sick), and pruritus (itching), which were generally mild or moderate in severity.
Najpogostejši neželeni učinki zdravila Zinforo (opaženi pri več kot 3 % bolnikov) so driska, glavobol, navzeja (slabost) in pruritus (srbenje), ki so bili na splošno blagi ali zmerni.
The most common side effects with Zydelig (which may affect more than 1 in 10 people) are infections (including lung infection caused by Pneumocystis jirovecii, and cytomegalovirus infections), neutropenia (low levels of neutrophils, a type of white blood cell), diarrhoea, increased liver enzymes in blood, rash, fever and increased blood fat levels.
Najpogostejši neželeni učinki zdravila Zydelig (ki lahko prizadenejo več kot 1 osebo od 10) so okužbe (vključno z okužbo pljuč, ki jo povzroča Pneumocystis jirovecii, in okužbo s citomegalovirusom), nevtropenija (nizke ravni nevtrofilcev, vrste belih krvnih celic), driska, povečanje ravni jetrnih encimov v krvi, izpuščaj, povišana telesna temperatura in povečanje ravni maščob v krvi.
The most common side effects with Zykadia (which may affect 1 or more people in 10) are diarrhoea, nausea (feeling sick), vomiting, tiredness, abnormal liver tests, abdominal pain (stomach ache), decreased appetite, constipation, rash, increases in the level of a waste product called creatinine in the blood (a possible sign of kidney problems), oesophageal disorder (problems affecting the gullet between mouth and stomach) and anaemia (low levels of red blood cells).
Najpogostejši neželeni učinki zdravila Zykadia (ki lahko prizadenejo več kot 1 osebo od 10) so driska, navzeja (slabost), bruhanje, utrujenost, nenormalni izvidi jetrnih testov, bolečine v trebuhu, zmanjšan tek, zaprtost, izpuščaj, zvišana raven odpadnega produkta, imenovanega kreatinin, v krvi (možen znak težav z ledvicami), s požiralnikom povezane motnje (težave, ki zadevajo cevast organ, ki vodi od ust do želodca) in anemija (nizka raven rdečih krvničk).
The most common side effects with Zytiga (seen in more than 1 patient in 10) were urinary tract infection, hypokalaemia (low blood potassium levels), hypertension (high blood pressure) and peripheral oedema (swelling of the limbs due to fluid retention).
Najpogostejši neželeni učinki zdravila Zytiga (opaženi pri več kot 1 bolniku od 10) so bili okužba sečil, hipokaliemija (nizka raven kalija v krvi), hipertenzija (visok krvni tlak) in periferni edemi (otekle okončine zaradi zastajanja tekočine).
The most common symptoms are: fever (high temperature) and skin rash.
povišana telesna temperatura (vročina) in izpuščaj na koži.
The most common symptoms of an infusion reaction included fever, chills, and hypertension.
Najpogostejši simptomi infuzijske reakcije so vključevali zvišano telesno temperaturo, mrzlico in hipertenzijo.
The most common symptoms of overdose with Siklos are:
Najpogostejši simptomi za prevelik odmerek zdravila Siklos so:
The most common symptoms that may occur after if you use more BiResp Spiromax than you should are trembling, headache or a rapid heartbeat.
Najpogostejši simptomi, ki se lahko pojavijo, če ste uporabili večji odmerek zdravila BiResp Spiromax, kot bi smeli, so tresenje, glavobol in hitro bitje srca.
The most common symptoms that may occur after if you use more DuoResp Spiromax than you should are trembling, headache or a rapid heartbeat.
Najpogostejši simptomi, ki se lahko pojavijo, če ste uporabili večji odmerek zdravila DuoResp Spiromax, kot bi smeli, so tresenje, glavobol in hitro bitje srca.
The most common treatment-emergent adverse reactions reported in clinical studies with adult epileptic patients, both in placebo and eslicarbazepine acetate groups were dizziness, somnolence, headache, and nausea.
Najpogostejše neželene učinki , povezane z zdravljenjem, o katerih so poročali v kliničnih študijah pri odraslih bolnikih z epilepsijo tako v placebo skupini kot tudi v skupini, ki je prejemala eslikarbazepinacetat, so omotica, zaspanost, glavobol in slabost.
The most common treatment-emergent adverse reactions reported in clinical studies with adult epileptic patients, both in placebo and eslicarbazepine acetate groups were dizziness, somnolence, headache, and nausea.
Najpogostejše neželene učinki, povezane z zdravljenjem, o katerih so poro čali v klini čnih študijah pri odraslih bolnikih z epilepsijo tako v placebo skupini kot tudi v skupini, ki je prejemala eslikarbazepinacetat, so omotica, zaspanost, glavobol in slabost.
The most common treatment-related adverse reactions were elevated liver chemistry tests (7.9%), nausea (7.4%), vomiting (5.5%), dyspnoea (3.2%), abdominal pain (2.7%), diarrhoea (2.7%), injection site reaction (2.2%), headache (2.0%), hypokalaemia (1.7%) and rash (1.7%).
Najpogostejši neţeleni učinki, povezani z zdravljenjem, so bili povišane vrednosti rezultatov preiskav kemije jeter (7,9 %), navzea (7,4 %), bruhanje (5,5 %), dispneja (3,2 %), bolečine v trebuhu (2,7 %), driska (2,7 % ), reakcija na mestu injiciranja (2,2 %), glavobol (2,0 %), hipokaliemija (1,7 %) in izpuščaj (1,7 %).
The most common type of seizures is generalised tonic-clonic seizures, a seizure type which can result in some cases in post-ictal confusion or memory impairment (see section 4.4).
Najpogostejša vrsta epileptičnih napadov so generalizirani tonični/klonični krči, ki lahko v nekaterih primerih povzročijo postiktalno zmedenost ali motnje spomina (glejte poglavje 4.4).
The most commonly (≥ 5 %) reported adverse drug reactions in patients with another indication treated with pramipexole were nausea, headache, dizziness and fatigue.
Najpogostejši (≥ 5 %) neželeni učinki, o katerih so poročali pri bolnikih z drugo indikacijo, ki so se zdravili s pramipeksolom, so bili slabost, glavobol, omotica in utrujenost.
The most commonly (≥ 5 %) reported adverse drug reactions in patients with Parkinson’s disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
Neželeni učinki, o katerih so najpogosteje poročali (≥ 5 %) pri bolnikih s Parkinsonovo boleznijo in so bili med zdravljenjem s pramipeksolom pogostnejši kot med jemanjem placeba, so bili slabost, diskinezija, hipotenzija, omotica, zaspanost, nespečnost, zaprtost, halucinacije, glavobol in utrujenost.
The most commonly (≥ 5%) reported adverse drug reactions in patients with other indication treated with pramipexole were nausea, headache, dizziness and fatigue.
Najpogostejši neželeni učinki (≥ 5 %), o katerih so poročali pri bolnikih z drugo indikacijo, ki so se zdravili s pramipeksolom, so bili slabost, glavobol, omotica in utrujenost.
The most commonly (≥ 5%) reported adverse drug reactions in patients with other indication treated with pramipexole were nausea, headache, dizziness and fatigue.
Najpogostnejši ( 5%) neželeni učinki, o katerih so poročali pri bolnikih z drugimi indikacijami, ki so se zdravili s pramipeksolom, so bili navzea, glavobol, omotica in utrujenost.
The most commonly (≥ 5%) reported adverse drug reactions in patients with Parkinson’s disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
Neželeni učinki, o katerih so najpogosteje poročali ( 5%) pri bolnikih s Parkinsonovo boleznijo in so bili med zdravljenjem s pramipeksolom pogostnejši kot med jemanjem placeba, so bili slabost, diskinezija, hipotenzija, omotica, zaspanost, nespečnost, zaprtost, halucinacije, glavobol in utrujenost.
The most commonly (≥ 5%) reported adverse drug reactions in patients with Restless Legs Syndrome treated with pramipexole were nausea, headache, dizziness and fatigue.
Najpogostnejši ( 5%) neželeni učinki, o katerih so poročali pri bolnikih s sindromom nemirnih nog, ki so se zdravili s pramipeksolom, so bili navzea, glavobol, omotica in utrujenost.
The most commonly (≥10%) occurring adverse reactions in all grades were anaemia (97.3%), leukopenia (95.7%), neutropenia (93.5%), thrombocytopenia (47.4%), and diarrhoea (46.6%).
Najpogostejši (≥10%) neželeni učinki, ki so zajemali vse stopnje so bili anemija (97,3%), levkopenija (95,7%), nevtropenija (93,5%), trombocitopenija (47,4%) in diareja (46,6%).
The most commonly (≥5%) occurring grade ≥3 adverse reactions in the cabazitaxel group were neutropenia (81.7%), leukopenia (68.2%), anaemia (10.5%), febrile neutropenia (7.5%), diarrhoea (6.2%).
Najpogostejši (≥5%) neželeni učinki ≥ 3. stopnje v skupini, ki je prejemala kabazitaksel, so bili nevtropenija (81,7%), levkopenija (68,2%), anemija (10,5%), febrilna nevtropenija (7,5%), driska (6,2).
The most commonly (≥5%) reported adverse reactions in patients with Parkinson’s disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
Neželeni učinki, o katerih so pri bolnikih s Parkinsonovo boleznijo najpogosteje poročali (≥ 5 %) in so bili med zdravljenjem s pramipeksolom pogostejši kot med jemanjem placeba, so bili slabost, diskinezija, hipotenzija, omotica, zaspanost, nespečnost, zaprtost, halucinacije, glavobol in utrujenost.
The most commonly observed adverse reaction associated with the use of Bronchitol during the initiation dose assessment is cough (3.6% of patients), (see section 4.4).
Najpogosteje ugotovljeni neželeni učinek, povezan z uporabo zdravila Bronchitol med oceno začetnega odmerka, je kašelj (3,6 % bolnikov) (glejte poglavje 4.4).
The most commonly observed adverse reaction associated with the use of Bronchitol is cough.
Najpogosteje ugotovljeni neželeni učinek, povezan z uporabo zdravila Bronchitol, je kašelj.
The most commonly observed adverse reaction associated with the use of Tasmar, occurring more frequently than in placebo-treated patients are listed in the table below.
Najpogosteje opaženi neželeni učinki, povezani z uporabo zdravila Tasmar, ki so se pojavili pogosteje kot pri s placebom zdravljenih bolnikih, so našteti v spodnji preglednici.
The most commonly observed adverse reactions which occurred more frequently in the lenalidomide groups compared to the control arm in the Phase III study were neutropenia (76.8%), thrombocytopenia (46.4%), diarrhoea (34.8%), constipation (19.6%), nausea (19.6%), pruritus (25.4%), rash (18.1%), fatigue (18.1%) and muscle spasms (16.7%).
Najpogosteje opaženi neželeni učinki, ki so se v študiji faze III pojavljali pogosteje v skupinah z lenalidomidom kot v kontrolni skupini, so bili nevtropenija (76,8 %), trombocitopenija (46,4 %), driska (34,8 %), zaprtje (19,6 %), navzea (19,6 %), pruritus (25,4 %), izpuščaj (18,1%), utrujenost (18,1 %) in mišični spazmi (16,7 %).
The most commonly observed resistance- associated mutations that emerged included L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C and M230I.
Najpogosteje opažene mutacije, povezane z rezistenco, ki so se pojavile, so vključevale L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C in M230I.
The most commonly observed severe symptoms with rivastigmine 9.5 mg/24 h transdermal patches were pruritus (1.7%) and erythema (1.1%).
Najpogosteje opažena huda simptoma s transdermalnimi obliži z rivastigminom 9,5 mg/24 h sta bila srbenje (1,7 %) in rdečina (1,1 %).
The most commonly occurring adverse reactions (≥ 20%) were diarrhoea, neutropenia, haemorrhage (e.g., bruising), musculoskeletal pain, nausea, rash, and pyrexia.
Najpogostejši (≥ 20%) neželeni učinki so bili diareja, nevtropenija, krvavitve (podplutbe), mišičnoskeletna bolečina, navzea, izpuščaj in zvišana telesna temperatura.
The most commonly reported (≥ 10%) medicinal product-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Z zdravilom povezane neželene reakcije, o katerih so najpogosteje poročali (≥ 10 %), so bile blaga navzea, bruhanje, driska, bolečine v trebuhu, utrujenost, mialgija, mišični krči in izpuščaj.
The most commonly reported ( 10%) drug- related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
Z zdravilom povezane neželene reakcije, o katerih so najpogosteje poročali (≥ 10 %), so bile blaga navzea, bruhanje, driska, bolečine v trebuhu, utrujenost, mialgija, mišični krči in izpuščaj.
The most commonly reported ADRs (occurring in ≥ 5% of patients treated with tocilizumab monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.
Najpogosteje opisani neželeni učinki (ki so se pojavili pri  5 % bolnikov, zdravljenih s tocilizumabom v monoterapiji ali v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili) so bili okužbe zgornjih dihal, nazofaringitis, glavobol, hipertenzija in zvišanje ALT.
The most commonly reported adverse drug reaction occurring in  10% of patients is headache.
Neželeni učinek, o katerem so najpogosteje poročali in se je pojavil pri  10 % bolnikov je glavobol.
The most commonly reported adverse drug reaction occurring in  10% of patients is headache.
Neželeni učinek, o katerem so najpogosteje poročali in se je pojavil pri  10 % bolnikov, je glavobol.
The most commonly reported Adverse Drug Reactions (ADRs) (occurring in ≥ 5% of patients treated with tocilizumab monotherapy or in combination with DMARDs) were upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased ALT.
Najpogosteje opisani neželeni učinki (ki so se pojavili pri  5 % bolnikov, zdravljenih s tocilizumabom v monoterapiji ali v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili) so bili okužbe zgornjih dihal, nazofaringitis, glavobol, hipertenzija in zvišanje ALT.
The most commonly reported adverse drug reactions (ADRs) were diarrhoea (42%) and rash (24%).
Najpogostejša neželena učinka zdravila sta bila driska (42 %) in izpuščaj (24 %).